Clinical translation of genetic predictors for type 2 diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 2, 2009, Pages 100-106

  Majithia, Amit R ^a,b,c   Florez, Jose C ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Genome wide association; Pharmacogenetics; Risk prediction; Type 2 diabetes

Indexed keywords

GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 1BETA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

AGENESIS; CELL FUNCTION; CELL MATURATION; FAMILY HISTORY; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RISK; GENOME; GLYCEMIC CONTROL; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INTROSPECTION; JUVENILE DIABETES MELLITUS; KIDNEY CYST; LOW DRUG DOSE; MATURITY ONSET DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHARMACOGENETICS; PHENOTYPE; POPULATION RISK; PREDICTION; PREDICTOR VARIABLE; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; GENETICS; PREDICTION AND FORECASTING; PROGNOSIS;

DIABETES MELLITUS, TYPE 2; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LINKAGE (GENETICS); PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 66149084915     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283292354     Document Type: Review

References (51)

1. Groop LC, Tuomi T. Noninsulin-dependent diabetes mellitus: a collision between thrifty genes and an affluent society. Ann Med 1997; 29:37-53.
2. Vaxillaire M, Froguel P. Genetic basis of maturity-onset diabetes of the young. Endocrinol Metab Clin North Am 2006; 35:371-384.
3. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320-323.
4. Florez JC. The new type 2 diabetes gene TCF7L2. Curr Opin Clin Nutr Metab Care 2007; 10:391-396.
5. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARg Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26:76-80.
6. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic b-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003; 52:568-572.
7. Nielsen EM, Hansen L, Carstensen B, et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003; 52:573-577.
8. Florez JC, Burtt N, de Bakker PI, et al. Haplotype structure and genotypephenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004; 53:1360-1368.
9. Sandhu MS, Weedon MN, Fawcett KA, et al. Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 2007; 39:951-953.
10. Winckler W, Weedon MN, Graham RR, et al. Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes 2007; 56:685-693.
11. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39:631-637.
12. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008; 322:881-888.
13. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445:881-885.
14. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007; 39:770-775.
15. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316:1336-1341.
16. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316:1341-1345.
17. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316:1331-1336.
18. Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40:638-645.
19. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 2007; 8:657-662.
20. Ludovico O, Pellegrini F, Di Paola R, et al. Heterogeneous effect of peroxisome proliferator-activated receptor γ2 Ala12 variant on type 2 diabetes risk. Obesity 2007; 15:1076-1081.
21. Yasuda K, Miyake K, Horikawa Y, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40:1092-1097.
22. Florez JC. The genetics of type 2 diabetes: a realistic appraisal circa 2008. J Clin Endocrinol Metab 2008; 93:4633-4642.
23. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316:889-894.
24. Florez JC. Newly identified loci highlight β cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 2008; 51:1100-1110.
25. Nishigori H, Yamada S, Kohama T, et al. Frameshift mutation, A263fsinsGG, in the hepatocyte nuclear factor-1β gene associated with diabetes and renal dysfunction. Diabetes 1998; 47:1354-1355.
26. Grarup N, Rose CS, Andersson EA, et al. Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes 2007; 56:3105-3111. An examination of T2D risk loci identified by the first round of GWAS, and association with quantitative glycemic traits, similar to [27•].
27. Grarup N, Andersen G, Krarup NT, et al. Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged Danes. Diabetes 2008; 57:2534-2540. An examination of new T2D risk loci identified by DIAGRAM, and association with quantitative glycemic traits in a Danish population.
28. Kirchhoff K, Machicao F, Haupt A, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 2008; 51:597-601. An examination of T2D risk loci and association with proinsulin-to-insulin conversion.
29. Bouatia-Naji N, Rocheleau G, Van Lommel L, et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 2008; 320:1085-1088. This study identifies the polymorphisms in the G6PC2 gene that are associated with FPG, but not with T2D risk.
30. Chen WM, Erdos MR, Jackson AU, et al. Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest 2008; 118:2620-2628.
31. Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet 2008; 41:77-81. A meta-analysis that identifies the melatonin receptor as associated with FPG and T2D risk.
32. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2008; 41:89-94. Results from a GWAS in a French cohort showing an association of variants in the melatonin receptor with FPG.
33. Lyssenko V, Nagorny CL, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2008; 41:82-88. This study demonstrates the association of variants in the melatonin receptor and T2D risk and shows that the MTNR1B is expressed on pancreatic b cells.
34. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008; 359:2208-2219. This article explores the prognostic benefit of adding 18 T2D-associated loci to known clinical risk predictors in a US cohort from Framingham, Massachusetts.
35. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359:2220-2232. This article explores the prognostic benefit of adding 11 T2D-associated loci to known clinical risk predictors in a Finnish cohort.
36. Lango H, Palmer CN, Morris AD, et al. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 2008; 57:3129-3135.
37. van Hoek M, Dehghan A, Witteman JC, et al. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a populationbased study. Diabetes 2008; 57:3122-3128.
38. McCarthy MI. Casting a wider net for diabetes susceptibility genes. Nat Genet 2008; 40:1039-1040.
39. Sagen JV, Raeder H, Hathout E, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004; 53:2713-2718.
40. Rafiq M, Flanagan SE, Patch AM, et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008; 31:204-209. This study demonstrates that patients with neonatal diabetes due to SUR1 mutations can be transitioned off insulin therapy and be successfully treated with sulfonylureas alone.
41. McCarthy MI, Hattersley AT. Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes. Diabetes 2008; 57:2889-2898.
42. Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362:1275-1281.
43. Sesti G, Laratta E, Cardellini M, et al. The E23K variant of KCNJ11 encoding the pancreatic b-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91:2334-2339.
44. Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003; 26:825-831.
45. Snitker S, Watanabe RM, Ani I, et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-γ2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004; 27:1365-1368.
46. Kang ES, Park SY, Kim HJ, et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005; 78:202-208.
47. Wolford JK, Yeatts KA, Dhanjal SK, et al. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 2005; 54:3319-3325.
48. Florez JC, Jablonski KA, Sun MW, et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007; 92:1502-1509.
49. Feng Y, Mao G, Ren X, et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008; 31:1939-1944. This article demonstrates that Chinese patients homozygous for the Ala/Ala variant of the sulfonylurea receptor have a statistically significant decrease in FPG compared with Ser/Ser homozygotes.
50. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 56:2178-2182. A retrospective study suggesting that diabetic individuals with TCF7L2 variants respond differently to sulfonylureas than to metformin.
51. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117:1422-1431. This article shows that normoglycemic individuals have differential hypoglycemic responses to metformin based on variation in OCT1.